This variability in expression profiles, along with the capacity of IL-13Rα2 to influence tumor cell survival and proliferation via receptor signaling mechanisms, renders IL-13Rα2 and EphA-2 promising targets for cancer therapy. This evidence concerns the gene EPHA2 and neoplasm.